Trial Profile
A Phase II, Randomized, Double-Blind, Multi-center, Placebo-controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2021
Price :
$35
*
At a glance
- Drugs Mixed amfetamine salts (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Shire
- 01 Jan 2018 Primary endpoint (PERMP (Permanent Product Measure of Performance) at 7 time points) has been met as per the results published in the Postgraduate Medicine
- 01 Jan 2018 Results of safety and efficacy published in the Postgraduate Medicine
- 20 Jun 2017 Results published in the Shire Media Release